Matthew Kamil, MD
Endocrinology, Diabetes & Metabolism · Concord, NHNPI 1427016567
Payments from drug & device makers
Across 695 payments — averaging $234.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$54K
- AstraZeneca$44K
- Novo Nordisk$27K
- Boehringer Ingelheim$18K
- Johnson & Johnson$15K
- Corcept Therapeutics$1K
- plus $2K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 158 | $54,408 |
| AstraZeneca | 262 | $44,426 |
| Novo Nordisk | 68 | $26,974 |
| Boehringer Ingelheim | 61 | $18,496 |
| Johnson & Johnson | 46 | $15,131 |
| Corcept Therapeutics | 9 | $1,315 |
| Amgen | 17 | $334 |
| Abbott | 7 | $264 |
| AbbVie | 12 | $216 |
| Radius Health, Inc. | 9 | $194 |
| Merck | 10 | $193 |
| Sanofi-aventis U.S. LLC | 8 | $187 |
| Tandem Diabetes Care, Inc. | 4 | $163 |
| Mannkind Corporation | 1 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Senseonics, Incorporated | 2 | $77 |
| Esperion Therapeutics, Inc. | 3 | $65 |
| Madrigal Pharmaceuticals | 3 | $59 |
| Medtronic | 3 | $51 |
| Amarin Pharma, Inc. | 3 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Lifescan, Inc. | 1 | $30 |
| Dexcom, Inc. | 1 | $26 |
| Clarus Therapeutics Inc. | 1 | $24 |
| Zealand Pharma US, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Bayer | 1 | $13 |
How this compares
$163,055 in reported general payments places this provider in the 90th percentile of 37 endocrinology, diabetes & metabolism providers in New Hampshire.
See all endocrinology, diabetes & metabolism providers in New Hampshire →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Concord
- Kevin AraoConcord$542
- John PorembaNashua$304K
- Michael DavidsonDover$204K
- Sushela ChaidarunLebanon$89K
- Dylan ThomasDover$17K
- Paul LabinsonNashua$5K
- Sreenija SuryadevaraLebanon$4K
- Harpreet RaiLebanon$2K
- Ellie ChuangNashua$1K
- Jhansi MaradanaDover$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.